Matrices Patents (Class 424/484)
  • Patent number: 10694741
    Abstract: The present invention relates to agrochemical combinations having enhanced rainfastness comprising a dithiocarbamate, a polycarboxylate salt and optionally one or more pesticides and/or a plant growth regulator and/or a micronutrient.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: June 30, 2020
    Assignee: UPL LIMITED
    Inventors: Sujata Dhondiram Desai, Satish Ekanath Bhoge, Jaidev Rajnikant Shroff, Vikram Rajnikant Shroff
  • Patent number: 10624930
    Abstract: The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: April 21, 2020
    Inventors: Silviu Itescu, Paul Simmons
  • Patent number: 10612001
    Abstract: The present invention concerns a method for obtaining an implantable cartilage gel for tissue repair of hyaline cartilage, comprising particles of chitosan hydrogel and cells that are capable of forming hyaline cartilage, said method comprising a step for amplification of primary cells in a three-dimensional structure comprising particles of physical hydrogel of chitosan or a chitosan derivative, then a step for re-differentiation and induction of the synthesis of extracellular matrix by said amplified cells, in the same three-dimensional structure, wherein said cells are primary articular chondrocytes and/or mesenchymal stem cells differentiated into chondrocytes. The present invention also concerns the cartilage gel obtained thereby, and its various uses for cartilage repair following a traumatic lesion or an osteoarticular disease such as osteoarthritis.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: April 7, 2020
    Inventors: Pascale Hazot, Frédéric Mallein Gerin
  • Patent number: 10576183
    Abstract: Disclosed herein are a cocoon-based, vascular patch and a method for manufacturing the same. The cocoon-based, vascular patch is manufactured by dividing a cocoon into two or more fragments in a predetermined form, the cocoon having a shell having a predetermined thickness. The cocoon-based vascular patch can be relatively simply manufactured in a more cost efficient manner than conventional vascular patches, and has excellent cell growth potential and biocompatibility.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: March 3, 2020
    Assignee: Republic of Korea (Management:Rural Development Administration)
    Inventors: Hae Yong Kweon, You Young Jo, Kwang Gill Lee, Hyun Bok Kim, Heui Sam Lee, Joo Hong Yeo, Seok Woo Kang
  • Patent number: 10576171
    Abstract: Novel cromolyn analogs useful as imaging agents for detecting atherosclerotic plaques and for treating atherosclerosis and Alzheimer's Disease, and methods of making the cromolyn analogs, are disclosed. The cromolyn analogs have the general formula: wherein: X is OH, C1-C6 alkoxyl; Y and Z are independently selected form a C1-C6 alkyl, C1-C6 alkoxyl, halogen, un-substiuted or C1-C6 substituted amine, 18F, 19F, or H; and n is 1, 2, or 3; and wherein for structure (I), if n are both 1 and Y and Z are both H and X is OH.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: March 3, 2020
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 10562974
    Abstract: A method of suppressing angiogenesis involves administering to a subject an isolated Fc fragment of an IgG1 antibody, or an IgG1 antibody.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 18, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Sandro De Falco
  • Patent number: 10548840
    Abstract: The present disclosure provides methods and systems for forming stable droplets as part of an emulsion. The emulsion may be, for example, formed by bringing an aqueous phase in contact with an oil phase at a droplet generation junction of a droplet generator. Droplets of the present disclosure may be used for holding compositions for various uses.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: February 4, 2020
    Assignee: Ojai Energetics PBC
    Inventors: William Kleidon, Justin Kirkland
  • Patent number: 10548885
    Abstract: The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, where in the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng/mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: February 4, 2020
    Inventors: Bruno Paillard, Laurence Del Frari, Valérie Brunner, Adrian Newman Tancredi, Mark Varney
  • Patent number: 10525165
    Abstract: Disclosed herein are a cocoon-based, dental barrier membrane for guided bone regeneration and a method for manufacturing the same. The cocoon-based, dental barrier membrane is manufactured by dividing a cocoon into two or more fragments in a predetermined form, the cocoon having a shell having a first thickness. The dental barrier membrane is biocompatible, has excellent tensile strength and porosity, and promotes osteogenesis in a bone defect.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: January 7, 2020
    Assignee: Republic of Korea (Management: Rural Development Administration)
    Inventors: You Young Jo, Hae Yong Kweon, Kwang Gill Lee, Joo Hong Yeo, Heui Sam Lee
  • Patent number: 10507178
    Abstract: An injectable carboxymethylcellulose (CMC) and methylcellulose (MC) hydrogel derived from the plant-based polysaccharide, cellulose, is provided which gels in situ and repairs the intervertebral disc in the spinal column or other cartilaginous tissues. One specific application is for replacement of the nucleus pulposus (NP), the central gelatinous region of the intervertebral disc, following injury or degeneration.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: December 17, 2019
    Assignee: Research Foundation of the City University of New York
    Inventors: Steven B. Nicoll, Devika Varma
  • Patent number: 10500249
    Abstract: The described invention provides compositions and methods for reducing progression of a fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the progression of the fibrosis being characterized by aberrant fibroblast proliferation and extracellular matrix deposition in the tissue. The method includes administering a therapeutic amount of a pharmaceutical composition containing a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier, wherein the therapeutic amount of the polypeptide is effective to reduce progression of the fibrosis, to treat remodeling of the tissue, or a combination thereof.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: December 10, 2019
    Assignee: MOERAE MATRIX INC.
    Inventors: Cynthia Lander, Colleen Brophy
  • Patent number: 10500201
    Abstract: Processes for preparing porous particles are disclosed, in which the resulting particles release an encapsulated active ingredient more readily in aqueous media than they do in alcoholic media. Also described are the particles themselves, as well as tamperproof, abuse-deterrent, dosage forms comprising the porous particles. The release characteristics of the porous particles make them useful for overcoming drug-abuse techniques, such as dose-dumping in alcoholic media.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: December 10, 2019
    Assignee: Lucideon Limited
    Inventors: Philip Robert Jackson, Mark Cresswell, Ian F. Campbell
  • Patent number: 10493179
    Abstract: The present invention provides for compositions and methods for preparing aqueous insoluble, ductile, flexible silk fibroin films. The silk films comprise silk fibroin and about 10% to about 50% (w/w) glycerol, and are prepared by entirely aqueous processes. The ductile silk film may be further treated by extracting the glycerol from and re-drying the silk film. Active agents may be embedded in or deposited on the glycerol modified silk film for a variety of medical applications. The films may be shaped into 3-dimensional structures, or placed on support surfaces as labels or coatings. The glycerol modified silk films of the present invention are useful in variety of applications such as tissue engineering, medical devices or implants, drug delivery, and edible pharmaceutical or food labels.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: December 3, 2019
    Assignee: Trustees of Tufts College
    Inventors: Shenzhou Lu, Xiaoqin Wang, Fiorenzo Omenetto, David L. Kaplan
  • Patent number: 10485763
    Abstract: The present invention provides: a composition for transarterial chemoembolization, comprising two types of biodegradable microbeads having different anticancer drug release characteristics; and a preparation method therefor. According to the present invention, a composition for transarterial chemoembolization exhibiting a desired anticancer drug release characteristic can be effectively prepared by controlling the mixing ratio of first and second biodegradable microbeads. Therefore, the present invention can be usefully applied to the transarterial chemoembolization of liver cancer.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: November 26, 2019
    Inventors: Don Haeng Lee, Young Hwan Park, Se Yoon Kim, Yixian Li
  • Patent number: 10471106
    Abstract: The composition having hydrolyzed collagen and Manuka honey includes hydrolyzed collagen in an amount ranging from between 5% to 95% by weight and Manuka honey in an amount ranging from between 5% to not greater than 50% by weight in water. The Manuka honey can have a methylglyoxal concentration greater than 100 mg/kg, and preferably greater than 550 mg/kg.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: November 12, 2019
    Inventor: George D. Petito
  • Patent number: 10426870
    Abstract: The present disclosure provides patterned biomaterials having organized cords and extracellular matrix embedded in a 3D scaffold. According, the present disclosure is provides compositions and applications for patterned biomaterials. Pre-patterning of these biomaterials can lead to enhanced integration of these materials into host organisms, providing a strategy for enhancing the viability of engineered tissues by promoting vascularization.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 1, 2019
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, The Massachusetts Institute of Technology
    Inventors: Christopher S. Chen, Jan D. Baranski, Ritika Chaturvedi, Michael T. Yang, Kelly Stevens, Sangeeta Bhatia
  • Patent number: 10429380
    Abstract: The present invention relates to measures for determining glucose and for diagnosing diseases based on impaired glucose metabolism. In particular the present invention relates to a device comprising a hydrogel having a glucose-binding protein and a ligand of the glucose-binding protein incorporated therein, wherein the hydrogel comprises a first hydrogel matrix made of alginate and a second hydrogel matrix which forms an interpenetrating network within the first hydrogel matrix. The invention further relates to the use of such a device for determining the glucose content in a sample and to the use of the device for diagnosing impaired glucose metabolism in a test subject.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: October 1, 2019
    Assignee: EyeSense AG
    Inventors: Achim Müller, Peter Herbrechtsmeier, Monika Knuth, Katharina Nikolaus
  • Patent number: 10420818
    Abstract: A method of treating a sphincter deficiency disorder (e.g., incontinence; gastrointestinal disorders) is carried out by administering stromal cell-derived factor 1 (SDF-1) to a sphincter or sphincter complex, such as a urethral or gastrointestinal sphincter (e.g., a rectal sphincter) of the subject in a treatment-effective amount.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: September 24, 2019
    Assignee: Wake Forest University Health Sciences
    Inventor: James K. Williams
  • Patent number: 10421941
    Abstract: The invention relates to a process for improving the solubility of dry cell culture media. Some dry powder cell culture media show poor dissolving properties and result in turbid solutions when they are dissolved in aqueous solutions. Using a stepwise procedure in which the amino acids present in the non-dissolving part are identified and added to a new batch in other particle sizes significantly reduces that problem.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: September 24, 2019
    Assignee: Merck Patent GmbH
    Inventor: Joerg Von Hagen
  • Patent number: 10413504
    Abstract: Described herein is an intra-vaginal drug delivery system comprising (i) a core comprising a first thermoplastic polymer and a first therapeutic agent, wherein the first therapeutic agent is dissolved in the first thermoplastic polymer, and (ii) a skin surrounding the core comprising a second thermoplastic polymer, wherein the first therapeutic agent is less permeable in the second thermoplastic polymer than the first thermoplastic polymer, and a second therapeutic agent in solid form, wherein the second therapeutic agent is loaded in a portion of the skin.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: September 17, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wouter de Graaff, Willy J. H. Verhoeven
  • Patent number: 10398686
    Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: September 3, 2019
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Girotti
  • Patent number: 10391123
    Abstract: The present invention provided an anticancer nano-silver composition for the treatment and prevention of cervical cancer. The composition contains nano-silver powder 3-200 mg/kg, carbomer 700-1000 mg/kg, triethanolamine 700-1000 mg/kg, glucose 2.8-3.2 g/kg, and water as remaining; of the nano-silver powder, wherein the purity of silver is ?99.99% and particle size is 1-5 nm. Experiments demonstrated that the anticancer nano-silver composition can be used to inhibit HeLa proliferation, and cause cell death. The anticancer nano-silver composition of the present invention can be used to manufacture medicaments for the treatment and prevention of cervical cancer.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: August 27, 2019
    Inventors: Jinjun Liu, Weiyi B. H. Situ, Qiangbai Li
  • Patent number: 10357460
    Abstract: The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets.
    Type: Grant
    Filed: September 26, 2012
    Date of Patent: July 23, 2019
    Assignee: Takeda AS
    Inventors: Jacob Mathiesen, Carsten M. Nielsen, Peder M. Olsen, Poul E. Bertelsen
  • Patent number: 10335487
    Abstract: This invention presents methods for targeting and killing types of cells or organisms using Magneto-Electric Nano-Particles under the control of an external magnetic field. A method was also presented for using Magneto-Electric Nano-Particles to stimulate or rejuvenate cells under an external magnetic field.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: July 2, 2019
    Inventor: Ping Liang
  • Patent number: 10322185
    Abstract: The present invention can provide a controlled drug release carrier formed by using a silk fibroin porous material, which has high drug controlled release rate, controllability of the drug controlled release speed, high strength, easy handleability, skin care properties from high biocompatibility, high water retentivity, and capability of efficiently retaining a drug.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: June 18, 2019
    Inventors: Kazutoshi Kobayashi, Kunihiro Suto, Naosuke Sumi, Hajime Inoue, Yasushi Tamada
  • Patent number: 10322142
    Abstract: The present invention relates to stable polymer matrix compositions comprising high concentrations (from about 1.5% w/w to about 3.5% w/w) sodium hyaluronate obtained from a Streptococcus zooepidemicus source and a non-ionic polymer. The polymer matrix composition further comprises polyethylene glycol and methylparaben, and utilizes ingredients that are of pharmaceutical or compendial grade. The polymer matrix compositions may optionally comprise an active ingredient. The present polymer matrix compositions may be used in the treatment of wounds, burns, certain dermatological conditions, vaginal dryness, and in topical, transdermal delivery and sustained release of active ingredients.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: June 18, 2019
    Inventors: Kevin Drizen, Jai Velusamy
  • Patent number: 10314940
    Abstract: A collagen-based therapeutic delivery device includes an insoluble synthetic collagen-fibril matrix comprising a polymerization product of soluble oligomeric collagen or a polymerization product of a mixture of soluble oligomeric collagen with one or more type of non-oligomeric soluble collagen molecules, such as, for example, soluble telocollagen and/or soluble atelocollagen, and an active agent dispersed throughout the collagen-fibril matrix or within a portion of the collagen-fibril matrix. A pre-matrix composition includes an aqueous solution including soluble collagen-fibril building blocks and an active agent in the aqueous solution. The soluble collagen-fibril building blocks include soluble oligomeric collagen or a mixture of soluble oligomeric collagen with non-oligomeric soluble collagen molecules. The building blocks are operable to self-assemble into a macromolecular synthetic collagen-fibril matrix in the absence of an exogenous cross-linking agent.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: June 11, 2019
    Assignee: Purdue Research Foundation
    Inventor: Sherry Voytik-Harbin
  • Patent number: 10307430
    Abstract: The present invention relates to pharmaceutical compositions comprising an ATP-sensitive potassium (K ATP) channel antagonist (e.g., sulfonylureas, meglitinides) and methods for treating hyperglycaemia and/or promoting growth of a premature and/or small for gestational age infant.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: June 4, 2019
    Inventors: Michel Polak, Marianne Berdugo Polak
  • Patent number: 10292997
    Abstract: The present invention relates to compositions and methods to improve the microenvironments in and around the wound in an effort to enhance healing. Specifically, the present invention comprises application of tissue and cells culture nutrient media, such as minimum essential media, supplemented with insulin and/or with substances exhibiting insulin-like activity, such as cinnamon or cinnamon extracts including but not limited to MHCP. The media is applied to the wound to stimulate the viable cells in the wound bed and the adjacent cells in the periphery of the wound to proliferate and grow into the wound in order to achieve wound closure.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: May 21, 2019
    Inventor: Ella Lindenbaum
  • Patent number: 10285936
    Abstract: The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: May 14, 2019
    Assignee: Laboratorios Farmacéuticos Rovi, S.A.
    Inventors: Guillermo Franco Rodríguez, Ibon Gutierro Aduriz
  • Patent number: 10279076
    Abstract: The present invention relates to a parenteral composition for maintaining the efficacy of a filler for a long time, containing a collagen hydrolysate as an active ingredient. The composition, according to the present invention, can maintain the efficacy of a hyaluronic acid filler for a longer time, thereby enabling the effect thereof to be maintained irrespective of a smaller frequency of filler operations, and thus there is an advantage of also reducing skin irritation. In addition, there is an advantage of enabling an immediate effect since an administration method is simple as a parenteral administration and enables direct penetration into the skin.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: May 7, 2019
    Inventors: Hyun Jung Shin, Jin Kyu Choi, Byung Gyu Kim, Dae Bang Seo
  • Patent number: 10272057
    Abstract: The invention relates to layered double hydroxide (LDH) materials and in particular to new methods of preparing improved LDH materials which have intercalated active anionic compounds (improved LDH-active anion materials). The improved LDH-active anion materials are characterized by their high degree of robustness, demonstrated by their high Particle Robustness Factor values, and by their ability to retain substantially all of the intercalated active anionic compound, in the absence of ion exchange conditions and/or at pH>4.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: April 30, 2019
    Inventors: Claire Thompson, Marcelo Leonardo Bravo Cordero, Dermot Michael O'Hare
  • Patent number: 10258566
    Abstract: The present invention relates to compositions, methods and kits for the treatment of bone particularly impaired or damaged bone.
    Type: Grant
    Filed: June 18, 2010
    Date of Patent: April 16, 2019
    Inventors: Charles E. Hart, Jeffrey O. Hollinger, Samuel E. Lynch
  • Patent number: 10253203
    Abstract: Articles are provided comprising a substrate and a coating. The coating comprises a polyelectrolyte complex having surface roughness. The polyelectrolyte complex has a thickness of at least 10 micrometers and a roughness of at least 1 micrometer.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: April 9, 2019
    Assignee: The Florida State University Research Foundation, Inc.
    Inventor: Joseph B. Schlenoff
  • Patent number: 10244787
    Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a polymer matrix and one or more flavorants and/or active ingredients embedded in the polymer matrix. The polymer matrix can include a copolymer of ethylene and one or more vinyl monomers or zein. For example, the polymer can be ethylene-vinyl acetate copolymer and/or ethylene-vinyl alcohol copolymer. In some cases, the oral product can include tobacco and/or nicotine.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 2, 2019
    Assignee: Altria Client Services LLC
    Inventors: Munmaya K. Mishra, Georgios D. Karles
  • Patent number: 10226532
    Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: March 12, 2019
    Inventors: Jeremy C. Wright, Wilma Tamraz, John J. Leonard, John W. Gibson, Keith E. Branham, Stefania Sjobeck, Brooks Boyd, Christopher M. Rubino
  • Patent number: 10213526
    Abstract: Provided are methods for preparing sterilized, gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth substrates. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: February 26, 2019
    Assignee: University of Pittsburgh-Of the Commonwealth System of Higher Education
    Inventors: Stephen F. Badylak, Christopher Lee Dearth, Timothy Joseph Keane, Jr., Neill Jordon Turner
  • Patent number: 10166254
    Abstract: The present invention relates to methods for treating and preventing graft-versus-host disease (GVHD) and radiation-induced tissue damage or organ failure. More particularly, methods of the present invention comprise administering a therapeutically effective amount of mesenchymal stem cell-educated macrophages (MEMs) to a subject to treat or prevent GVHD, bone marrow failure, radiation-induced tissue damage or organ failure, or a condition associated with aberrant inflammation.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: January 1, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Peiman Hematti, Myriam N. Bouchlaka, Christian M. Capitini
  • Patent number: 10154865
    Abstract: An orthopedic implant, such as a bone screw with a self-tapping thread, is formed of a biodegradable material such as a magnesium alloy. A bioactive surface coating is provided on the implant, such as at the threading. The coating contains micro-abrasives which assist with screw/implant penetration, and/or contains microcapsules containing lubricant, wherein the microcapsules rupture from pressure and frictional heat as the implant penetrates bone.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: December 18, 2018
    Assignee: BIOTRONIK AG
    Inventors: Ullrich Bayer, Daniel Lootz
  • Patent number: 10123530
    Abstract: The invention relates to the treatment of blood, blood products and organs for the removal and/or detoxification of amyloid-beta oligomers.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: November 13, 2018
    Inventor: Dieter Willbold
  • Patent number: 10111810
    Abstract: The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.
    Type: Grant
    Filed: March 29, 2013
    Date of Patent: October 30, 2018
    Assignee: Aquestive Therapeutics, Inc.
    Inventors: Robert K. Yang, Richard C. Fuisz, Garry L. Myers, Joseph M. Fuisz
  • Patent number: 10045947
    Abstract: The invention provides polymer compositions for cell and drug delivery.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: August 14, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: Sidi A. Bencherif, David J. Mooney, David Edwards, Roger Warren Sands
  • Patent number: 10047154
    Abstract: An Ang2 specific antibody, a method of inhibiting angiogenesis or a method of treating a disease related to the activation and/or overproduction of Ang2 using the antibody, and a composition for diagnosing a disease related to the activation and/or overproduction of Ang2 including the antibody.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: August 14, 2018
    Inventors: Seok Kyun Kim, Sang Yeul Han, Kwang Hoon Lee, Kyung Eun Kim, Chung Ho Kim, Yong In Kim, Hyung-Chan Kim, Yoon Sook Lee, Hyo Seon Lee
  • Patent number: 10016428
    Abstract: The present invention refers to a pharmaceutical composition of sildenafil citrate in the form of a suspension for administration orally that comprises water as a vehicle and xanthan gum and hypromellose as suspension agents, that is highly stable and allows the efficient masking of the active ingredient's bitter taste. It also refers to a procedure for the preparation of said suspension and to a container that contains it and that is provided with a dosing device for its administration. This composition of sildenafil citrate in the form of a suspension is suitable for administration orally for the treatment of masculine sexual dysfunction.
    Type: Grant
    Filed: March 22, 2016
    Date of Patent: July 10, 2018
    Inventors: Fernando Martínez-Alzamora, Antonia Gómez Calvo, Miguel Rizo Martínez, Nuria Sanz Menéndez
  • Patent number: 10006003
    Abstract: The present technology provides methods for preparing a flowable amniotic composition derived from amniotic membrane of humans. Various embodiments of the method for preparing the amniotic composition may comprise mincing the amniotic membrane in a cryopreservation solution, cryopreservation, homogenization, filtration, centrifugation, and resuspension of a pellet in a cell solution to produce the flowable amniotic composition. The amniotic composition may comprise approximately 2.7 million viable cells per milliliter. The viability of the cells may be substantially stable for at least six months at ?18° C. Some preparations of the amniotic composition may have a flowability that may be at least partially characterized by a viscosity suitable for delivery to the target site through at least a 22 gauge needle.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 26, 2018
    Assignee: Surgenex, LLC
    Inventors: Eliott Spencer, Doug Schmid, Abel Bullock
  • Patent number: 10000742
    Abstract: The present disclosure generally relates to a method and device for inactivation and dry storage, under ambient conditions, of a biological sample containing RNA virus. Methods for collecting and recovering RNA from a biological sample and subsequent analysis for a virus are also provided.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: June 19, 2018
    Assignee: General Electric Company
    Inventors: Erik Leeming Kvam, Robert Scott Duthie, John Richard Nelson
  • Patent number: 9999705
    Abstract: The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: June 19, 2018
    Assignee: Gel-Del Technologies, Inc.
    Inventors: David B. Masters, Eric P. Berg
  • Patent number: 9987213
    Abstract: The present invention relates to the composition and method of use for the topical application of the potent androgen hormone dihydrotestosterone (DHT), used alone or in fixed combination with other hair growth medications; including other androgens, bimatoprost, other prostamides, prostaglandins, minoxidil or apocrine hair growth factors to promote and enhance hair growth of terminal mustache hair, beard hair, also chest hair, and other male androgen sensitive or dependent hair growth in humans or animals.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: June 5, 2018
    Inventor: Edward Dunne Corboy, Jr.
  • Patent number: 9968621
    Abstract: Parenteral (injectable) celecoxib emulsions and nanoemulsions are disclosed as are their use to treat pain in patients so afflicted. The emulsions are generally oil in water emulsions often comprised of an oil phase including an oil and a lecithin wherein the mean droplet size of the discontinuous oil phase is about 200 nanometers or less.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: May 15, 2018
    Assignee: Dr. Reddy's Laboratories Ltd.
    Inventors: Franklin Okumu, Jan-Jon Chu, Julie Ann Webb, Rafael Anthony Sabino, Andrew Xian Chen
  • Patent number: 9968552
    Abstract: Oral pharmaceutical dosage form comprising tromethamine and a NSAID selected from the group comprising ibuprofen, naproxen and flurbiprofen, characterized in that it also comprises a compound selected from the group comprising glycine, vitamin B6 and mixtures thereof.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: May 15, 2018
    Inventors: Leonardo Marchitto, Francesca Mariotti, Lorella Ragni